Utilize our plasmid DNA expertise in viral and non-viral vectors for seamless support from discovery to commercialization

Gene therapy offers groundbreaking solutions for delivering therapeutic genes into target cells, with two primary approaches: viral and non-viral vector gene therapy. Viral vector gene therapy demands meticulous attention to detail, from discovery to commercial production, to ensure safety, efficacy, and scalability.

Non-viral vector gene therapy presents a promising alternative, minimizing risks associated with viral vectors and offering versatile delivery options like transposon-based systems, lipid-based vectors, and direct plasmid DNA transfer. Both viral and non-viral methods pose significant challenges but hold immense potential for treating a wide range of genetic disorders and diseases.

Aldevron rises to these challenges with determination and innovation, providing seamless support, comprehensive workflows, and expertise from discovery through clinical trials and commercial launch. Our unwavering commitment to excellence and relentless pursuit of improvement enables our clients to achieve groundbreaking advancements in their mission to transform lives.